Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors

Expert Opinion on Therapeutic Patents

Volumn 6, Issue 11, 1996, Pages 1147-1164

  Fink, C A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6,7,8,12B OCTAHYDRO 7 (2 MERCAPTO 3 PHENYLPROPIONAMIDO) 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; 2,3,4,5 TETRAHYDRO 3 (2 MERCAPTO 3 PHENYLPROPIONAMIDO) 2 | |OXO 1H BENZAZEPINE 1 ACETIC ACID; 7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ALADOTRIL; BMS 182657; CGS 27025; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ER 32897; ER 32945; MDL 101264; MDL 101287; MDL 102353; MDL 102769; MEMBRANE METALLOENDOPEPTIDASE; MIXANPRIL; N (2 MERCAPTOMETHYL 3 PHENYLBUTYRYL)ALANINE; OMAPATRILAT; RB 106; SAMPATRILAT; UK 63831; UK 79942; UK 81252; UNCLASSIFIED DRUG;

CONGESTIVE HEART FAILURE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG STRUCTURE; ENZYME INHIBITION; HYPERTENSION; PATENT; REVIEW;

EID: 0029809157     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.6.11.1147     Document Type: Review

References (0)